Related Experiment Video
Updated: Jul 14, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Suicidal ideation in epilepsy and levetiracetam therapy
1The Neuropsychiatry Research Group, Department of Neurology, Amedeo Avogadro University, Novara, Italy. marcomula@yahoo.it
Epilepsy & Behavior : E&B
|June 5, 2007
Summary
Antiepileptic drugs (AEDs) like levetiracetam (LEV) may be linked to suicidal ideation, particularly in patients with mood disorders. Early recognition of suicidal thoughts during LEV therapy is crucial for preventing attempts.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Limited research exists on the association between antiepileptic drugs (AEDs) and suicidal ideation.
- Suicidal ideation is a serious adverse effect that requires prompt recognition and management.
Purpose of the Study:
- To investigate the occurrence of suicidal ideation in patients treated with levetiracetam (LEV).
- To identify potential clinical variables associated with suicidal ideation during LEV therapy.
Main Methods:
- Retrospective evaluation of a case registry.
- Analysis of 517 patients receiving levetiracetam (LEV).
Main Results:
- Four patients (0.7%) reported suicidal ideation.
- All cases of suicidal ideation occurred in patients with a concurrent mood disorder.
- Suicidal ideation emerged early in the course of LEV therapy.
- The psychopathological features of suicidal ideation were consistent across patients and resembled interictal dysphoric disorder of epilepsy.
Conclusions:
- Levetiracetam (LEV) may be associated with an increased risk of suicidal ideation, especially in patients with pre-existing mood disorders.
- Early monitoring for suicidal ideation is recommended for patients initiating LEV therapy.
- The observed features suggest a potential link between LEV, mood disorders, and epilepsy-related dysphoria.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...